Aripiprazole in the treatment of Huntington's disease: A case series

Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E. Mencacci, Barbara Poletti, Andrea Ciarmiello, Ferdinando Squitieri, Vincenzo Silani

Research output: Contribution to journalArticlepeer-review


Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington's disease (HD). Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions. Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalNeuropsychiatric Disease and Treatment
Issue number1
Publication statusPublished - 2009


  • Aripiprazole
  • Chorea
  • Huntington's disease
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Aripiprazole in the treatment of Huntington's disease: A case series'. Together they form a unique fingerprint.

Cite this